[1]

YANG Yifan, YANG Yanwei, ZHANG Di, XIE Yin, ZHANG Yong, CHEN Xulin, GAO Sutao, GENG Xingchao, QU Zhe. Quality Control and Test Methods of Human Induced Pluripotent Stem Cells [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 728-734.

[2]

REN Yuke, JIANG Hua, LI Lulu, LI Shuangxing, HUO Guitao, YANG Yanwei, ZHANG Di, HUANG Ying, GENG Xingchao, LIN Zhi, QU Zhe. Research Advances in the Pathogenesis of Cytokine Release Syndrome Induced by CAR-T Cell Therapy [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 735-741.

[3]

REN Yuke, QU Zhe, LAI Zixuan, ZHANG Di, ZHAO Yongtian, YANG Yanwei, LI Shuangxing, HUO Guitao, ZHOU Xiaobing, LIN Zhi, GENG Xingchao. Pharmacodynamic Evaluation of CAR-T Cell Products Based on Deep Learning Convolutional Neural Network Recognition [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 742-748.

[4]

TANG Jiong, ZENG Yuqi. One Case of Oculomotor Paralysis Caused by Sugemalimab Injection [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 812-814.

[5]

ZHONG Xinru, YANG Deying, GUAN Tangming, CHEN Ju, JIANG Dongbo. Research Progress in Adverse Reactions Caused by Obinutuzumab in the Treatment of Follicular Lymphoma [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 831-835.

[6]

GAO Caiyun, WANG Boyuan, GAO Xiaojie. Research Progress in Correlations between SGLT2 Inhibitors and Malignant Tumors [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 836-840.

[7]

ZHANG Yunhui, CHEN Haoyun, ZHONG Luhua, FANG Caifu, HUANG Huanjun, GUO Chenchen, DONG Xinyi, SHI Feng, LIANG Weiting. 159 Cases of Adverse Reactions to Immune Checkpoint Inhibitors [J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 442-446.

[8]

CHEN Lingbin, HUANG Zhixiong, ZHENG Cailin, WU Jinneng, CHEN Zhou. Adverse Event Signals for Osimertinib-Induced Muscle Toxicity Based on FAERS Database [J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 447-451.

[9]

[10]

[11]

ZENG Ji, ZHANG Jinke, WANG Li, CHEN Jun, MENG Xudong, NING Jing, HUANG Cheng. One Case of Rash Caused by Apalutamide Combined with Goserelin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 472-474.

[12]

BU Zixuan, XUE Mengwei, TIAN Jiawei, KE Kaile, WANG Ziying, LI Xiao, LU Tiangong. Interventions of Guizhi Fuling Pills in Properties of Ovarian Cancer Stem Cells [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 263-270.

[13]

LONG Minjuan, ZHAO Xu, GUO Longxin, CAI Yuhan, LIN Li, ZHU Shengkai, LIU Wenlong, SONG Haibo, XIAO Xiaohe. Big Data Analysis of Liver Adverse Reactions Monitoring of Chinese and Western Medicines Based on Age Correction and Risk Warning for Dermatologic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 271-275.

[14]

ZHU Zhipeng, LYU Qiang, YE Xiaofei, GUO Xiaojing. Disproportionality of Adverse Events to KRAS G12C Inhibitors Based on the FAERS Database [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 297-304.

[15]

FAN Liping, LU Shu, CAI Yueping, WAN Yuxiang, SUN Huiyuan. Kanglaite Combined with Gefitinib for Mid-Late Stage Lung Cancer：a Meta-Analysis and Trial Sequential Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 316-323.

PDF (PC)

Knowledge